List view / Grid view
8 September 2015 | By Victoria White
In two studies, Opdivo showed an estimated 18 month overall survival rate of 27% to 28% in patients with previously treated squamous non-small cell lung cancer (NSCLC)...
7 September 2015 | By Victoria White
The MHRA has said it is now seeing greater appreciation among pharmaceutical sector companies of the skills required for the essential Responsible Person role...
7 September 2015 | By Cherwell Laboratories
Company maintains focus on quality to meet customer expectations...
7 September 2015 | By Victoria White
The announcement follows a review that found that CDF spending would rise to around £410 million for this year - an over-spend of £70m from the budget set in April 2015...
7 September 2015 | By Victoria White
NICE has recommended that pembrolizumab is made available on the NHS as a treatment for some patients with advanced melanoma which is either unresectable or metastatic...
7 September 2015 | By Victoria White
Dr Roychowdury brings over 15 years of comprehensive pharmaceutical industry experience and 14 years of patient care and academic research to the role with Celyad...
7 September 2015 | By Victoria White
Faron's admission to AIM will support development of its lead candidate, Traumakine, into a Phase III Study and the development of its preclinical cancer immunotherapy candidate, Clevegen...
4 September 2015 | By Victoria White
The EC has approved Farydak in combination with bortezomib and dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma...
4 September 2015 | By Victoria White
RoActemra has been recommended by NICE for the treatment of patients with severe rheumatoid arthritis whose disease has not responded to intensive therapy with a combination of cDMARDs...
4 September 2015 | By Victoria White
The FDA has approved Brilinta tablets at a new 60mg dose to be used in patients with a history of heart attack beyond the first year...
4 September 2015 | By Victoria White
Breakthrough therapy designation has been granted to ACE910 for the prophylactic treatment of people with haemophilia A with factor VIII inhibitors...
4 September 2015 | By Victoria White
Allergan is to acquire AqueSys for a $300 million upfront payment and milestone payments related to AqueSys' lead development programmes, including XEN45...
4 September 2015 | By Victoria White
While generic acute coronary syndrome (ACS) drugs currently lead in market revenues, the share of branded therapeutics is expected to increase to more than 60% of the total market by 2019...
3 September 2015 | By Victoria White
The extent of data breaches in the pharmaceutical sector has been revealed by a survey that shows 60% have lost important data...
3 September 2015 | By Victoria White
PHE is calling for pregnant women to take up the whooping cough vaccine as surveillance figures confirm that whooping cough activity remains at raised levels in England...
